E-LIB Suche - Ergebnisse für: Paz-Ares, L.

1

104TiP Phase Ib/IIa study of ATR inhibitor tuvusertib + ant..:

Paz-Ares, L. ; Cappuzzo, F. ; Yamamoto, N....
ESMO Open. 9 (2024) - p. 102683 , 2024

Link: https://doi.org/10.1016/..

2

63P Treatment-free survival (TFS) in patients (pts) with mN..:

Reck, M. ; Regan, M. ; Carbone, D.P....
ESMO Open. 9 (2024) - p. 102642 , 2024

Link: https://doi.org/10.1016/..

3

11P Patritumab deruxtecan (HER3-DXd) in previously treated ..:

Hayashi, H. ; Goto, Y. ; Yu, H.A....
ESMO Open. 9 (2024) - p. 102590 , 2024

Link: https://doi.org/10.1016/..

4

59P Datopotamab deruxtecan (Dato-DXd) in patients with prev..:

Girard, N. ; Okamoto, I. ; Lisberg, A.E....
ESMO Open. 9 (2024) - p. 102638 , 2024

Link: https://doi.org/10.1016/..

5

195MO Tarlatamab in previously treated small cell lung canc..:

Hummel, H-D. ; Champiat, S. ; Garcia, M.E. Olmedo...
ESMO Open. 9 (2024) - p. 102768 , 2024

Link: https://doi.org/10.1016/..

6

214TiP Tarlatamab after chemoradiotherapy in limited-stage ..:

Hummel, H-D. ; Paz-Ares, L. ; Blackhall, F....
ESMO Open. 9 (2024) - p. 102787 , 2024

Link: https://doi.org/10.1016/..

7

7P Patient-relevant endpoints from PAPILLON: Amivantamab pl..:

Paz-Ares, L. ; Veillon, R. ; Majem, M....
ESMO Open. 9 (2024) - p. 102586 , 2024

Link: https://doi.org/10.1016/..

8

Nivolumab plus chemotherapy in first-line metastatic non-sm..:

Borghaei, H. ; O'Byrne, K.J. ; Paz-Ares, L....
ESMO Open. 8 (2023) 6 - p. 102065 , 2023

Link: https://doi.org/10.1016/..

9

Ramucirumab plus erlotinib versus placebo plus erlotinib in..:

Garon, E.B. ; Reck, M. ; Nishio, K....
ESMO Open. 8 (2023) 4 - p. 101580 , 2023

Link: https://doi.org/10.1016/..

10

13MO Safety and efficacy of tusamitamab ravtansine in combi..:

Isambert, N. ; Nagy, T. ; Ravoire, M....
Journal of Thoracic Oncology. 18 (2023) 4 - p. S46-S47 , 2023

Link: https://doi.org/10.1016/..

11

3P Exploratory efficacy analysis by smoking status in PD-L1..:

Paz-Ares, L. ; García-Campelo, M.R. ; Isla Casado, M.D....
Immuno-Oncology and Technology. 20 (2023) - p. 100474 , 2023

Link: https://doi.org/10.1016/..

12

P1.21-07 Quantitative Assessment of OX40L and Its Associati..:

Baena, J. ; Calles, A. ; Aguado, C....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S236-S237 , 2023

Link: https://doi.org/10.1016/..

13

OA05.03 Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NS..:

Yu, H.A. ; Goto, Y. ; Hayashi, H....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S53-S54 , 2023

Link: https://doi.org/10.1016/..

14

P2.17-06 Efficacy of Platinum after Lurbinectedin + DOX or ..:

Navarro, A. ; Smit, E. ; Carcereny, E....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S380-S381 , 2023

Link: https://doi.org/10.1016/..

15

P1.23-08 Clinical Utility of Combined Plasma and Tissue NGS..:

Bote de Cabo, H. ; Siringo, M. ; García-Lorenzo, E....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S258 , 2023

Link: https://doi.org/10.1016/..